AI Meets Biotech is Germany's Next Innovation Wave

In January 2026, a start-up called Aignostics introduced Atlas 2, a new state-of-the-art pathology foundation model: it analyses digital tissue images, revealing subtle cellular patterns in tumors that can accelerate the development of more precise cancer therapies. With Atlas 2, the Berlin-based spin-out of three top research institutions is one of the most compelling examples of the emerging AI4Bio trend. 

Rooted in Berlin’s vibrant life science and tech ecosystem and built in collaboration with leading institutions such as the hospital Charité in Berlin, the LMU university Munich and the US-based Mayo Clinic, Aignostics showcases what becomes possible when world-class medical data, strong academic networks, and a growing AI talent pool come together. 

This unique combination makes Germany a natural hub for AI-driven biomedical innovation. The country stands on the cusp of a new biotech boom that’s propelled by advances in AI – a transformation that is reshaping not only where research happens, but how it is done. For internationally active companies looking for a foothold in Europe, this opens up substantial business opportunities – not least because they can draw on Germany's formidable strengths as one of the world's premier research and development locations.

“Germany offers pharmaceutical and biotech companies a highly attractive environment,” says Agnieszka Rzepka of the Healthcare Export Initiative at Germany Trade & Invest (GTAI). “As Europe's largest healthcare market, the German healthcare industry contributes around 12 per cent to total gross value added.”

AI inspiring partnerships

Beyond Aignostics, a strong cohort of major German and international companies remains firmly committed to AI-driven biotech development in Germany. And the list is growing: Bayer is collaborating with AI company Recursion Pharmaceuticals; Boehringer Ingelheim has partnered with Google Quantum AI; and Roche has joined forces with Munich-based AI company Temedica. 

High-growth start-ups are also reshaping the landscape. Munich-based Tubulis, for example, announced a partnership in 2025 with Mindpeak, a leading AI company for pathology automation.

AI partnerships offer tangible advantages for the pharmaceutical industry: they broaden research programs, accelerate laboratory workflows, and improve the odds of success in fields such as oncology, immunology and neurology. French pharmaceutical company Sanofi is the case in point. 

“We have integrated AI into numerous areas of our research and development,” says Thomas Klabunde, Global Head of Translational Disease Modelling at the firm’s German subsidiary.

Accelerating drug discovery with AI

The AI4Bio trend is making inroads across many areas of Sanofi's operations. Machine learning, for instance, can identify previously hidden patterns in so-called multi-omics data – that is, data integrating multiple levels of biological information, beginning with genomics – to enable a comprehensive analysis of a person's health status. By harnessing vast quantities of data, the company gains deeper insights into complex biological systems and disease mechanisms.

Sanofi deploys AI to shorten research timelines through improved predictive modelling and to automate time-consuming tasks. Its Frankfurt location plays a pivotal role in this effort. The site is a key node in the company's European research network, housing centers of excellence for AI-based drug design and multi-specific protein engineering.

A high-performance ecosystem 

Renowned institutions such as Goethe University Frankfurt, the Max Planck Institute for Biological Intelligence, and the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) form an innovation network concentrated in life sciences clusters in the Rhine-Main region, Berlin and Munich. 

“The interdisciplinary networking of academic and industrial expertise creates excellent conditions in this country for using AI in a targeted manner to accelerate research processes and translate scientific innovations into therapeutic solutions even more efficiently,” says Klabunde.

A further powerful stimulus for Germany's AI4Bio scene comes from Brussels. Numerous European Union (EU) funding programs – among them Horizon Europe, the European Innovation Council, EU4Health, and the planned “Important Project of Common European Interest” – are backing research projects, start-ups and the development of Europe-wide production capacities. The new European Health Data Space, meanwhile, will make a continental trove of electronic patient health data available for research.

Making the difference

The growing number of AI-driven biotech projects is bolstering Germany’s status as central Europe's hub for medical innovation. The country boasts an exceptional concentration of life sciences players, with more than 700 biotech companies and more than 50,000 skilled professionals. 

The market that is shaping up offers ideal conditions for research and clinical development, manufacturing and global commercialization.

“Anyone looking to invest in European biotechnology cannot ignore Germany,” says Rzepka. “An ecosystem of substantial funding, modern infrastructure and strong intellectual property protection creates a comprehensive package unmatched in Europe.”